Development of vascular disrupting agents

Vascular Disruptive Agents for the Treatment of Cancer

Volumn , Issue , 2010, Pages 1-27

  Dougherty, Graeme J ^a   Chaplin, David J ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Magdalen Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892753813     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6609-4_1     Document Type: Chapter

References (192)

1. Aitken RA, Bibby MC, Bielefeldt F, Double JA, Laws AL, Mathieu AL, Ritchie RB, Wilson DW (1998) Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-Heteroaryl derivatives. Arch Pharm (Weinheim) 331:405-411
2. Alghisi GC, Ponsonnet L, Ruegg C (2009) The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4:e4449
3. Algire GH, Legallais FY, Anderson BF (1952) Vascular reactions of normal and malignant tissues in vivo. V. Role of hypotension in the action of bacterial polysaccharide on tumors. J Natl Cancer Inst 12:1279-1295
4. Anton K, Glod J (2009) Targeting the tumor stroma in cancer therapy. Curr Pharm Biotechnol 10:185-191
5. Arnberg N (2009) Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol 19:165-178
6. Baguley BC (2001) Small-molecule cytokine inducers causing tumor necrosis. Curr Opin Investig Drugs 2:967-975
7. Baguley BC (2003) Antivascular therapy of cancer: DMXAA. Lancet Oncol 4:141-148
8. Baguley BC, Wilson WR (2002) Potential of DMXAA combination therapy for solid tumors. Expert Rev Anticancer Ther 2:593-603
9. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482-487Baka
10. S, Clamp AR, Jayson GC (2006) A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets 10:867-876
11. Baker AH, Kritz A, Work LM, Nicklin SA (2005) Cell-selective viral gene delivery vectors for the vasculature. Exp Physiol 90:27-31
12. Balkwill FR (1989) Tumour necrosis factor. Br Med Bull 45:389-400
13. Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L (2006) Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res 12:2575-2582
14. Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA (2006) Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer 118:2639-2643
15. Beerepoot LV, Radema SA, Witteveen EO, Thomas T, Wheeler C, Kempin S, Voest EE (2006) Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 24:1491-1498
16. Bertout JA, Patel SA, Simon MC (2008) The impact of O2 availability on human cancer. Nat Rev Cancer 8:967-975
17. Billard C, Menasria F, Quiney C, Faussat AM, Finet JP, Combes S, Kolb JP (2008) 4-arylcoumarin analogues of combretastatins stimulate apoptosis of leukemic cells from chronic lymphocytic leukemia patients. Exp Hematol 36:1625-1633
18. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ (2002a) ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 54:1497-1502
19. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002b) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8:1974-1983
20. Blaschuk OW, Rowlands TM (2000) Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev 19:1-5
21. Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D, Zardi L (2003) Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 102:4384-4392
22. Boyland E, Boyland ME (1937) Studies in tissue metabolism: the action of colchicine and B. typhosus extract. Biochem J 31:454-460
23. Boyland E, Boyland ME (1940) Studies in tissue metabolism: the action of colchicine on transplanted, induced and spontaneous mouse tumours. Biochem J 34:280-284
24. Busch W (1866) Einflub von erysipel. Beliner Klin Wschr 3:245-246
25. Cai SX (2007) Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2:79-101
26. Cao Y (2009) Tumor angiogenesis and molecular targets for therapy. Front Biosci 14:3962-3973
27. Carpenito C, Davis PD, Dougherty ST, Dougherty GJ (2002) Exploiting the differential production of angiogenic factors within the tumor microenvironment in the design of a novel vasculartargeted gene therapy-based approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 54:1473-1478
28. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666-3670
29. Chaplin DJ, Hill SA (2002) The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54:1491-1496
30. Chaplin DJ, Horsman MR (1994a) The effect of artificially induced ischemia on tumour cell survival. Adv Exp Med Biol 345:437-443
31. Chaplin DJ, Horsman MR (1994b) The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies. Radiother Oncol 30:59-65
32. DJ, Olive PL, Durand RE (1987) Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 47:597-601
33. Chaplin DJ, Pettit GR, Parkins CS, Hill SA (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 27:S86-S88
34. Chaplin DJ, Horsman MR, Siemann DW (2006) Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 7:522-528
35. Chase JL (2008) Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28:23S-30S
36. Coley WB (1891) Contribution to the knowledge of sarcoma. Ann Surg 14:199-220
37. Coley WB (1914) The treatment of malignant tumors by repeated inoculations of erysipelas and Bacillus prodigiosus . Brussels: M. Weissenbruch
38. Cooney MM, Radivoyevitch T, Dowlati A, Overmoyer B, Levitan N, Robertson K, Levine SL, DeCaro K, Buchter C, Taylor A, Stambler BS, Remick SC (2004) Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 10:96-100
39. Cowan PJ, Shinkel TA, Fisicaro N, Godwin JW, Bernabeu C, Almendro N, Rius C, Lonie AJ, Nottle MB, Wigley PL, Paizis K, Pearse MJ, d'Apice AJ (2003) Targeting gene expression to endothelium in transgenic animals: a comparison of the human ICAM-2, PECAM-1 and endoglin promoters. Xenotransplantation 10:223-231
40. Dai C, McAninch RE, Sutton RE (2004) Identification of synthetic endothelial cell-specific promoters by use of a high-throughput screen. J Virol 78:6209-6221
41. Dancer A, Julien S, Bouillot S, Pointu H, Vernet M, Huber P (2003) Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice. Gene Ther 10:1170-1178
42. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834
43. Dass CR, Choong PF (2006) Selective gene delivery for cancer therapy using cationic liposomes: in vivo proof of applicability. J Control Release 113:155-163
44. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA (2002) ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 62:7247-7253
45. De Palma M, Venneri MA, Naldini L (2003) In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 14:1193-1206
46. Demartis S, Tarli L, Borsi L, Zardi L, Neri D (2001) Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med 28:534-539
47. Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139
48. Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23:217-225
49. Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9:267-282
50. Denekamp J (1991) The current status of targeting tumour vasculature as a means of cancer therapy: an overview. Int J Radiat Biol 60:401-408
51. Denekamp J (1993) Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196
52. Denekamp J, Hill SA, Hobson B (1983) Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol 19:271-275
53. Denekamp J, Dasu A, Waites A (1998) Vasculature and microenvironmental gradients: the missing links in novel approaches to cancer therapy? Adv Enzyme Regul 38:281-299
54. Dickens DS, Jubinsky PT (2009) Therapeutic strategies for targeting mononuclear phagocytes in cancer. J Pediatr Hematol Oncol 31:14-17
55. Dienst A, Grunow A, Unruh M, Rabausch B, Nor JE, Fries JW, Gottstein C (2005) Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J Natl Cancer Inst 97:733-747
56. Dong Z, Nor JE (2009) Transcriptional targeting of tumor endothelial cells for gene therapy. Adv Drug Deliv Rev 61:542-552
57. Dougherty GJ, Dougherty ST (2009) Exploiting the tumor microenvironment in the development of targeted cancer gene therapy. Cancer Gene Ther 16:279-290
58. Dougherty GJ, Davis PD, Dougherty ST (2004) Vascular-targeted cancer gene therapy. Expert Opin Biol Ther 4:1911-1920
59. Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62:3408-3416
60. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
61. Edelstein ML, Abedi MR, Wixon J, Edelstein RM (2004) Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 6:597-602
62. el-Zayat AA, Degen D, Drabek S, Clark GM, Pettit GR, Von Hoff DD (1993) In vitro evaluation of the antineoplastic activity of combretastatin A-4, a natural product from Combretum caffrum (arid shrub). Anticancer Drugs 4:19-25
63. Enback J, Laakkonen P (2007) Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 35:780-783
64. Enderlen E (1896) Klinische und experimentelle Studien zur Frage der Torsion des Hodens. Dtsch Z Chir 43:177
65. Fang L, Shen L, Fang Y, Hu Y, He Q, Yang B (2008) MZ3 can induce G2/M-phase arrest and apoptosis in human leukemia cells. J Cancer Res Clin Oncol 134:1337-1345
66. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60:4066-4069
67. Fitzwilliams DCL (1927) The treatment of carcinoma by lead colloids. Br Med J 1:822
68. Flick DA, Gifford GE (1986) Production of tumor necrosis factor in unprimed mice: mechanism of endotoxin-mediated tumor necrosis. Immunobiology 171:320-328
69. Folkman J (1999) Angiogenic zip code. Nat Biotechnol 17:749
70. Follin F (1852) De la cryptorchidie chez l'homme Mem Soc Biol
71. Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment: targets for antiangiogenesis and normalization. Microvasc Res 74:72-84
72. Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119:2205-2212
73. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM (2001) Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting acti vity in vivo. Anticancer Res 21:93-102
74. Gavard J (2009) Breaking the VE-cadherin bonds. FEBS Lett 583:1-6
75. Gaya AM, Rustin GJ (2005) Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17:277-290
76. Gotlieb AI (1990) The endothelial cytoskeleton: organization in normal and regenerating endothelium. Toxicol Pathol 18:603-617
77. Gould S, Westwood FR, Curwen JO, Ashton SE, Roberts DW, Lovick SC, Ryan AJ (2007) Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 99:1724-1728
78. Graulich W, Nettelbeck DM, Fischer D, Kissel T, Muller R (1999) Cell type specificity of the human endoglin promoter. Gene 227:55-62
79. S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I, Barshack I, Hodish I, Yaacov N, Bangio L, Goncharov T, Wallach D, Harats D (2004) Transcriptioncontrolled gene therapy against tumor angiogenesis. J Clin Invest 113:1017-1024
80. Gresser I (1987) A. Chekhov, M.D., and Coley's toxins. N Engl J Med 317:457
81. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW (2003) Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 19:575-589
82. Grothey A, Ellis LM (2008) Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 14:170-177
83. Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16:80-88
84. Hanna E, Quick J, Libutti SK (2009) The tumour microenvironment: a novel target for cancer therapy. Oral Dis 15:8-17
85. He J, Luster TA, Thorpe PE (2007) Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res 13:5211-5218
86. Heath VL, Bicknell R (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6:395-404
87. Hellner H (1933) Die örtlichen Kreislaufstörungen des Hodens. Bruns Beitr Klin Chir 158:225
88. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1994) The effect of vinca alkaloids on tumour blood flow. Adv Exp Med Biol 345:417-422
89. Hinnen P, Eskens FA (2007) Vascular disrupting agents in clinical development. Br J Cancer 96:1159-1165
90. Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, Feder B, Waitsman A, Barshack I, Goldberg I, Mazaki-Tovi S, Peled M, Harats D (2009) Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Cancer Biol Ther 8:424-432
91. Hoption Cann SA, van Netten JP, van Netten C, Glover DW (2002) Spontaneous regression: a hidden treasure buried in time. Med Hypotheses 58:115-119
92. Hoption Cann SA, van Netten JP, van Netten C (2003) Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 79:672-680
93. Huang G, Chen L (2008) Tumor vasculature and microenvironment normalization: a possible mechanism of antiangiogenesis therapy. Cancer Biother Radiopharm 23:661-667
94. Huang X, Bennett M, Thorpe PE (2005) A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res 65:4408-4416
95. Hundsberger H, Verin A, Wiesner C, Pfluger M, Dulebo A, Schutt W, Lasters I, Mannel DN, Wendel A, Lucas R (2008) TNF: a moonlighting protein at the interface between cancer and infection. Front Biosci 13:5374-5386
96. Jager U, Zhao Y, Porter CD (1999) Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol 73:9702-9709
97. Lippert JW, III (2007) Vascular disrupting agents. Bioorg Med Chem 15:605-615
98. Kaspar M, Trachsel E, Neri D (2007) The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res 67:4940-4948
99. Kelland L (2007) Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. Curr Opin Mol Ther 9:86-91
100. Kesmodel SB, Spitz FR (2003) Gene therapy for cancer and metastatic disease. Expert Rev Mol Med 5:1-18
101. Kiaris H, Trimis G, Papavassiliou AG (2008) Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy. Curr Med Chem 15:3062-3067Klagsbrun
102. Klagsbrun M, Moses MA (2008) Obituary: M. Judah Folkman 1933-2008). Nature 451 781
103. Kouraklis G (1999) Progress in cancer gene therapy. Acta Oncol 38:675-683
104. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT (1998) Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 72:1844-1852
105. Kuckleburg CJ, Tiwari R, Czuprynski CJ (2008) Endothelial cell apoptosis induced by bacteriaactivated platelets requires caspase-8 and -9 and generation of reactive oxygen species. Thromb Haemost 99:363-372
106. Kuhn H, Konrad J, Holtz S, Salameh A, Gessner C, Hammerschmidt S, Wirtz H (2006) Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung Cancer 54:149-153
107. Lee JS, Gotlieb AI (2005) Microtubules regulate aortic endothelial cell actin microfilament reorganization in intact and repairing monolayers. Histol Histopathol 20:455-465
108. Leiter J, Downing V, Hartwell JL, Shear MJ (1950) Damage induced in sarcoma 37 with podophyllin, podophyllotoxin alpha-peltatin, beta-peltatin, and quercetin. J Natl Cancer Inst 10:1273-1293
109. Leiter J, Downing V, Hartwell JL, Shear MJ (1952) Damage induced in sarcoma 37 with chemical agents. II. Trivalent and pentavalent arsenicals. J Natl Cancer Inst 13:365-378
110. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59:6033-6037
111. Li YM, Broome JD (1999) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59:776-780
112. Li H, Price DK, Figg WD (2007) ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs 18:563-568
113. Liu Y, Deisseroth A (2006) Tumor vascular targeting therapy with viral vectors. Blood 107:3027-3033
114. London NR, Whitehead KJ, Li DY (2009) Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 12:149-158
115. Lorusso G, Ruegg C (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130:1091-1103
116. LoRusso PM, Gadgeel SM, Wozniak A, Barge AJ, Jones HK, DelProposto ZS, DeLuca PA, Evelhoch JL, Boerner SA, Wheeler C (2008) Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26:159-167
117. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB (2009) The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78-86
118. Ludford RJ (1948) Factors determining the action of colchicine on tumour growth. Br J Cancer 2:75-86
119. Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, Thorpe PE (2006) Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem 281:29863-29871
120. Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111-137
121. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116:2610-2621
122. Mariotti A, Perotti A, Sessa C, Ruegg C (2007) N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs 16:451-465
123. Mbeunkui F, Johann DJJ (2009) Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63:571-582
124. McCarthy EF (2006) The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 26:154-158
125. McKeage MJ (2008) The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer. Expert Opin Investig Drugs 17:23-29
126. MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99:2006-2012
127. McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone- 4-acetic acid/DMXAA) 1800 mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65:192-197
128. Miflet J (1879) Über die pathologischen Veränderungen des Hodens, welche durch Störungen der lokalen Blutzirkulation veranlat werden Arch Klin Chir 24:399
129. Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG (2005) The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7:912-920
130. Mottram JC (1923) Observations on the combined action of colloidal lead and radiation on tumours. Br Med J 1:132-133
131. Nabel EG, Plautz G, Nabel GJ (1991) Gene transfer into vascular cells. J Am Coll Cardiol 17:189B-194B
132. Nicklin SA, Reynolds PN, Brosnan MJ, White SJ, Curiel DT, Dominiczak AF, Baker AH (2001) Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 38:65-70
133. Nicklin SA, White SJ, Nicol CG, Von Seggern DJ, Baker AH (2004) In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors. J Gene Med 6:300-308
134. Nikitenko LL (2009) Vascular endothelium in cancer. Cell Tissue Res 335:223-240
135. Noske HD, Kraus SW, Altinkilic BM, Weidner W (1998) Historical milestones regarding torsion of the scrotal organs. J Urol 159:13-16
136. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231
137. Parker AL, Fisher KD, Oupicky D, Read ML, Nicklin SA, Baker AH, Seymour LW (2005) Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J Drug Target 13:39-51
138. Parkins CS, Hill SA, Lonergan SJ, Horsman MR, Chadwick JA, Chaplin DJ (1994) Ischaemia induced cell death in tumors: importance of temperature and pH. Int J Radiat Oncol Biol Phys 29:499-503
139. Pasqualini R, Arap W (2002) Translation of vascular diversity into targeted therapeutics. Ann Hematol 81 Suppl 2:S66-S67
140. Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L (2009) Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours. Ann Oncol 20:741-745
141. Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E, Rafii S (2008) The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111:1951-1961
142. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D (1989) Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 45:209-211
143. Philpott M, Joseph WR, Crosier KE, Baguley BC, Ching LM (1997) Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76:1586-1591
144. Philpott M, Ching LM, Baguley BC (2001) The antitumour agent 5,6-dimethylxanthenone-4- acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor. Eur J Cancer 37:1930-1937
145. Pilat MJ, Lorusso PM (2006) Vascular disrupting agents. J Cell Biochem 99:1021-1039
146. Pinto MM, Sousa ME, Nascimento MS (2005) Xanthone derivatives: new insights in biological activities. Curr Med Chem 12:2517-2538Pober
147. Pober JS (1987) Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. Ciba Found Symp 131:170-184
148. Ran S, Thorpe PE (2002) Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int J Radiat Oncol Biol Phys 54:1479-1484
149. Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58:4646-4653
150. Ran S, Downes A, Thorpe PE (2002) Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res 62:6132-6140
151. Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE (2005a) Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 11:1551-1562
152. Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG (2005b) The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 7:486-496
153. Rehman F, Rustin G (2008) ASA404: update on drug development. Expert Opin Investig Drugs 17:1547-1551
154. Rhee J, Hoff PM (2005) Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 6:1701-1711
155. Ribatti D (2009) The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des 15:345-352
156. Ruegg C, Mutter N (2007) Anti-angiogenic therapies in cancer: achievements and open questions. Bull Cancer 94:753-762
157. Rustin GJ, Galbraith SM, Anderson H, Stratford M, Folkes LK, Sena L, Gumbrell L, Price PM (2003) Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21:2815-2822
158. Seed L, Slaughter DP, Limarzi LR (1940) Effect of colchicine on human carcinoma. Surgery 7:696-709
159. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA 2007, Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome, Neoplasia, 9, 128-135
160. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA (2007) Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia 9:128-135
161. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS (2006) Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 313:1785-1787
162. Shear MJ (1944) Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J Natl Cancer Inst 4:461-476
163. Shear MJ, Turner FC, Perrault A (1943) Chemical treatment of tumors. Isolation of haemorrhageproducing fractions fromSerratia marcescens (Bacillus prodrigiosus) culture filtrate (Bacillus prodrigiosus) culture filtrate J Natl Cancer Inst 4:81-97
164. Shi W, Siemann DW (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19:1045-1050
165. Siemann DW, Chaplin DJ (2007) An update on the clinical development of drugs to disable tumor vasculature. Expert Opin Drug Discov 2:1-11
166. Siemann DW, Horsman MR (2004) Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther 4:321-327
167. Siemann DW, Horsman MR (2009) Vascular targeted therapies in oncology. Cell Tissue Res 335:241-248
168. Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60:1233-1240
169. Siemann DW, Shi W (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28:2027-2031
170. Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499Development of Vascular Disrupting Agents 27
171. Siemann DW, Chaplin DJ, Walicke PA (2009) A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 18:189-197
172. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
173. Thorpe PE, Ran S (2002) Mapping zip codes in human vasculature. Pharmacogenomics J 2:205-206
174. Thorpe PE, Chaplin DJ, Blakey DC (2003) The first international conference on vascular targeting: meeting overview. Cancer Res 63:1144-1147
175. van Heeckeren WJ, Bhakta S, Ortiz J, Duerk J, Cooney MM, Dowlati A, McCrae K, Remick SC (2006) Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 24:1485-1488
176. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG (2002) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99:7866-7871
177. Vestweber D, Winderlich M, Cagna G, Nottebaum AF (2009) Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 19:8-15
178. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, Bohlen P, Chaplin DJ, May C, Rafii S (2005) Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 115:2992-3006
179. Wakelee HA, Schiller JH (2005) Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer. Clin Lung Cancer 7 Suppl 1:S31-S38
180. Walshe WW (1844) The Anatomy, Physiology, Pathology and Treatment of Cancer, William D. Ticknor & Co: Boston.
181. West CM, Price P (2004) Combretastatin A4 phosphate. Anticancer Drugs 15:179-187
182. White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH (2004) Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 109:513-519
183. White K, Buning H, Kritz A, Janicki H, McVey J, Perabo L, Murphy G, Odenthal M, Work LM, Hallek M, Nicklin SA, Baker AH (2008) Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther 15:443-451
184. Woglom WH (1923) A critique of tumour resistance. J Cancer Res 7:283-311
185. Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, Feherenbacher L, O'Reilly S, Allegra CJ (2009) A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP Protocol C-08. J Clin Oncol 27:15s. (abstr LBA4)
186. Wood FC (1926) Use of colloidal lead in the treatment of cancer. J Am Med
187. Work LM, Ritchie N, Nicklin SA, Reynolds PN, Baker AH (2004) Dual targeting of gene delivery by genetic modification of adenovirus serotype 5 fibers and cell-selective transcriptional control. Gene Ther 11:1296-1300
188. Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N, Leike K, Odenthal M, Drebber U, Hallek M, Baker AH (2006) Vascular bed-targeted in vivo gene delivery using tropismmodified adeno-associated viruses. Mol Ther 13:683-693
189. Xu D, Fang L, Zhu Q, Hu Y, He Q, Yang B (2008) Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells. Pharmazie 63:528-533
190. Zhang B (2008) Targeting the stroma by T cells to limit tumor growth. Cancer Res 68:9570-9573
191. Zhou S, Kestell P, Baguley BC, Paxton JW (2002) 5,6-dimethylxanthenone- acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs 20:281-295
192. Zweifel M, Jayson G, Reed N, Osborne R, Hassan B, Shreeves G, Poupard L, Walicke PA, Balkissoon J, Chaplin D, Rustin G (2009) Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: final phase II trial results. J Clin Oncol 27:15s. (suppl; abstr 5502)